Manisha Desai
Publication Details
-
Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy.
J Clin Oncol. 2006; (19): 3075-80
Up to 50% of patients treated with intravesical agents for superficial bladder cancer will experience recurrence. Response rates to second-line intravesical therapies range from 20% to 40%. For these high-risk patients, novel agents are necessary to prevent recurrence. Docetaxel is a microtubule depolymerization inhibitor with unique physiochemical properties, making it an excellent candidate for investigation as an intravesical agent.
Help